📊 CNTX Key Takeaways
Investment Thesis
Context Therapeutics is a pre-revenue pharmaceutical company with severe cash burn and negative profitability metrics that render traditional financial analysis unreliable. While the company maintains strong liquidity with $76.9M in cash, its burn rate of $17.4M annually in operating losses creates a runway of approximately 4-5 years assuming no further fundraising, making near-term viability dependent entirely on clinical trial success and upcoming capital raises.
CNTX Strengths
- Substantial cash position of $76.9M provides near-term operational runway
- Strong balance sheet with minimal debt (Debt/Equity of 0.00x) and $73.2M stockholders equity
- Excellent current and quick ratios (13.10x) indicating minimal near-term liquidity constraints
- Revenue growth of 112.7% YoY suggests emerging commercial traction or milestone achievements
CNTX Risks
- Massive operating losses (-$25.9M) and net losses (-$23.1M) with no clear path to profitability
- Negative free cash flow of -$17.5M annually with operating cash burn consuming capital reserves
- Pre-clinical/early-stage pharmaceutical company dependent on uncertain drug development outcomes
- Extremely negative profitability margins (Operating Margin -1158.1%, Net Margin -1032.9%) indicate fundamental unprofitability
- Current revenue of $2.2M is immaterial relative to operating expenses, suggesting minimal commercial validation
Key Metrics to Watch
- Operating cash burn rate and cash runway duration
- Clinical trial progress and regulatory milestone achievements
- Revenue growth trajectory and commercialization progress
- Need for and terms of future capital raises
CNTX Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 13.10x current ratio provides a solid financial cushion.
CNTX Profitability Ratios
CNTX vs Healthcare Sector
How Context Therapeutics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CNTX Balance Sheet & Liquidity
CNTX 5-Year Financial Trend
5-Year Trend Summary: Context Therapeutics Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.50 indicates the company is currently unprofitable.
CNTX Growth Metrics (YoY)
CNTX Capital Allocation
CNTX SEC Filings
Access official SEC EDGAR filings for Context Therapeutics Inc. (CIK: 0001842952)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CNTX
What is the AI rating for CNTX?
Context Therapeutics Inc. (CNTX) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CNTX's key strengths?
Substantial cash position of $76.9M provides near-term operational runway. Strong balance sheet with minimal debt (Debt/Equity of 0.00x) and $73.2M stockholders equity.
What are the risks of investing in CNTX?
Massive operating losses (-$25.9M) and net losses (-$23.1M) with no clear path to profitability. Negative free cash flow of -$17.5M annually with operating cash burn consuming capital reserves.
What is CNTX's revenue and growth?
Context Therapeutics Inc. reported revenue of $2.2M.
Does CNTX pay dividends?
Context Therapeutics Inc. does not currently pay dividends.
Where can I find CNTX SEC filings?
Official SEC filings for Context Therapeutics Inc. (CIK: 0001842952) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CNTX's EPS?
Context Therapeutics Inc. has a diluted EPS of $-0.24.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.